Trophos and MS-Repair partners present promising data on novel approach in multiple sclerosis

25-Nov-2010 - France

Trophos SA announced that Trophos and partners in the MS-Repair consortium delivered an oral presentation detailing Trophos’ novel approach in multiple sclerosis (MS) at the recent Society for neuroscience (SfN) Meeting. The data presented demonstrate that olesoxime, Trophos’ lead compound, is a promising candidate for neuroaxonal repair and remyelination in white matter diseases, notably multiple sclerosis. The MS-Repair project is supported by the French Agence Nationale pour la Recherche (ANR).

Novel compounds to promote axon repair and remyelination in multiple sclerosis (Bordet et al.). It showed that Olesoxime dose-dependently promoted oligodendrocyte maturation and myelination in several in vitro (oligodendrocyte progenitor cells, oligodendrocyte – neuron co-cultures, organotypic brain slice cultures) and two in vivo models (cuprizone and lysophosphatidyl choline induced demyelination).

The results were obtained by a collaboration supported by the ANR project MS-Repair awarded to Trophos and two academic partners in Marseille, Dr Pascale Durbec at the Institut de Biologie du Développement de Marseille Luminy CNRS – Université de la Méditerranée UMR6216 and Dr Angèle Viola at the Centre de Résonance Magnétique Biologique et Médicale CNRS – Université de la Méditerranée UMR6612, in February 2009.

Olesoxime (TRO19622) is the lead compound of Trophos' proprietary cholesterol-oxime compound family of mitochondrial pore modulators, developed for their ability to promote the function and survival of neurons and other cell types under disease-relevant stress conditions through interactions with the mitochondrial permeability transition pore (mPTP). The data announced today show that olesoxime also has the ability to promote remyelination in addition to providing neuroprotection. Olesoxime is currently in two pivotal clinical efficacy studies, the first in over 500 patients with Amyotrophic Lateral Sclerosis with results expected in the fourth quarter of next year (see releases of May 9 2009 and March 17 2010) and the second a recently started pivotal clinical study in Spinal Muscular Atrophy (see release of October 15 2010).

https://www.bionity.com/en/news/126491/trophos-and-ms-repair-partners-present-promising-data-on-novel-approach-in-multiple-sclerosis.html